糖尿病血管内皮损害标志物的检测及其与尿白蛋白的关系

目的　对比观察2型糖尿病(DM)及糖尿病肾病(DN)患者血管内皮损害标志物,分析其与白蛋白尿相关性。方法　6 8例2型糖尿病患者根据尿白蛋白排泄率分为正常白蛋白尿组(Ⅰ组)和微量白蛋白尿组(Ⅱ组) ,同时以健康成人作为对照组(Ⅲ组) ,分别检测其循环内皮细胞(CEC)、vonWillebrand因子(vWF)、内皮素- 1 (ET - 1 )的变化,并分析其相关性。结果　DM患者CEC、vWF和ET - 1明显增高,尤其是DN组(P <0 .0 5 ) ,各指标间以及与尿白蛋白排泄呈正相关。结论　2型DM患者在出现白蛋白尿前已存在血管内皮功能异常,其白蛋白排泄与血管内皮功能障碍程度有一定相关性。     

镇痛灵对雄性1型糖尿病大鼠性功能的影响

目的 :本实验以成年雄性大鼠为研究对象 ,观察和探讨中药镇痛灵对糖尿病大鼠性功能的影响。　方法 :3～ 5月龄雄性Wistar大鼠 32只 ,随机分为糖尿病组 2 2只 ,正常对照组 10只。 72h后 ,将造模成功的糖尿病大鼠随机分为 2组 :未治疗组 ;镇痛灵治疗组。第 5周测血糖 ,阿朴吗啡勃起实验后 ,乙醚麻醉下断头取血 ,分离血清 ,取一侧睾丸组织制成匀浆液 ,测定血清及组织匀浆中NO及NOS水平。　结果 :糖尿病大鼠与正常对照组比较 ,血清NO、NOS明显降低 ,差异有高度显著性 (P <0 .0 0 1) ;镇痛灵治疗组血清NO、NOS值与未治疗组比较明显升高 ,差异有显著性 (P <0 .0 1) ;阿朴吗啡勃起实验证实 ,镇痛灵治疗组大鼠阴茎勃起次数明显多于未治疗组 ,差异有显著性(P <0 .0 1) ,而与正常对照组比较 ,差异无显著性 (P >0 .0 5 )。　结论 :复方中药合剂镇痛灵有降血糖作用 ,对糖尿病并发的性功能障碍有一定治疗作用。     

周围神经损伤后勃起功能障碍的治疗进展

外伤、手术可因盆神经丛和 (或 )海绵体神经损伤而造成勃起功能障碍。较理想的治疗方法是使损伤神经自我再生修复 ,完全恢复勃起功能。本文综述近年来勃起神经损伤后再生修复方面的研究进展 ,试图寻找出一种促进损伤的勃起神经再生的最佳方法     

夜间电子生物阻抗测量装置对阴茎勃起功能障碍的检测

目的 :探讨夜间电子生物阻抗测量装置 (NEVA)在阴茎勃起功能障碍的诊断中的应用价值。方法 :对 4 1例主诉阴茎勃起功能障碍者 (障碍组 ) 19例主诉无勃起功能障碍但有射精障碍者 (无障碍组 )进行NEVA检测。结果 :障碍组夜间试验中的夜间勃起的次数、阴茎勃起的最大体积改变、最长持续时间等客观指标均要差于无障碍组 ,差异有统计学意义 (P <0 .0 1)。结论 :NEVA为非侵入性检测、可鉴别心理性阴茎勃起功能障碍和严重的器质性勃起功能障碍 ,且对勃起功能障碍的定性和定量具有一定的客观性。     

Tadalafil in the treatment of erectile dysfunction; an overview of the clinical evidence

Prevalence and severity of erectile dysfunction (ED) increase with aging and are often associated with illnesses, like diabetes mellitus, heart disease, and hypertension, pathologically characterized by endothelial dysfunction and whose prevalence increases with age. The assumption that ED is mainly a neurovascular disease is supported by the evidence that specific phosphodiesterase type 5 (PDE5) inhibition produces an efficient erection in a wide range of ages and conditions. The availability of specific PDE5 inhibitors has enabled the development of effective treatment strategies, in this contest, tadalafil may be considered as the least “typical” PDE5 inhibitor. In clinical trials, tadalafil significantly enhanced, in patients of different ages, all efficacy outcomes across disease etiologies and severities. With an effectiveness lasting up to 36h, tadalafil allows patients to choose when to have sexual activities without the need to time it, showing positive feedback in terms of quality of life related to the treatment. Headache and dyspepsia were the most frequent side-effects of tadalafil, followed by back pain, nasal congestion, myalgia, and flushing, but the impact that long time action could have on effectiveness and safety is not yet entirely defined. The aim of this article is to critically review the available evidence from the tadalafil clinical research program and give the physician a rational approach for intervention in the treatment of ED and related diseases.     

万艾可治疗ED时对BPH引起LUTS改善的研究

目的 :探索、研究万艾可在治疗阴茎勃起功能障碍 (ED)时对由良性前列腺增生 (BPH)引起的下尿路症状(LUTS)的影响。　方法 :32例ED同时伴有BPH的研究对象 ,采用IIEF 5问卷表和IPSS评分表 ,在服用万艾可前和服药后 6个月分别各填写一次 ,应用单因素方差分析对所得到的前后评分进行统计学分析。结果 :在服药前32例ED中 ,轻、中、重分别为 14、13、5例 ,BPH中轻、中、重分别为 3、15、14例 ;服药后IIEF 5评分平均上升4 2 .36 % ,IPSS评分平均下降 2 0 .14 % ,两者在统计学上都有显著性差异 ,P <0 .0 1。　结论 :在治疗中老年性ED合并BPH中 ,应用万艾可既能治疗ED ,取得完美的性生活 ,又能达到改善由BPH引起的LUTS。万艾可是一治疗ED有效的药物 ,但对于前列腺基质平滑肌亦有辅助性松弛作用 ,因此也有助于BPH时LUTS的缓解。     

保留盆腔自主神经的全直肠系膜切除的临床应用及评价

目的探讨保留盆腔自主神经（PANP）的全直肠系膜切除（TME）在男性直肠癌低位保肛术中的应用。方法回顾性分析传统手术、TME和PANP＋TME在男性直肠癌保肛手术中的应用，对各组病人肿瘤下缘距肛门距离、3年存活率、局部复发率、排尿功能、性功能作一评价。结果TME组和PANP＋TME组手术病人的肿瘤下缘距肛门距离较传统手术组明显缩短（P〈0．05）；3组的3年存活率分析差异无显著性（P〉0．05）；TME组和PANP＋TME组的局部复发率较传统手术组明显降低（P〈0．05）；传统手术组、TME组、PANP＋TME组的排尿障碍、勃起功能障碍和射精功能障碍的发生率逐渐降低，3组间两两比较差异均有显著性（P〈0．05）。PANP手术分型与排尿障碍、勃起功能障碍和射精功能障碍分级呈正相关（P〈0．05）。结论TME可以降低直肠癌的局部复发率，降低排尿障碍和性功能障碍的发生率；PANP和TME结合使排尿障碍和性功能障碍的发生率更加降低，PANP手术保留神经越彻底，手术后排尿障碍、性功能障碍的发生率越低。     

Pre-Implantation Multiple Cytokine mRNA Expression Analysis of Donor Lung Grafts Predicts Survival After Lung Transplantation in Humans

While current donor selection with clinical findings is generally effective, the imprecise nature of the assessment forces clinicians to remain on the conservative side. A reliable biological marker would assist donor selection and would improve donor organ utilization. We collected biopsies from 169 donor lungs before implantation. Expression levels of IL-6, IL-8, IL-10, TNF-alpha, IFN-gamma and IL-1beta were measured by quantitative real-time RT-PCR (qRT-PCR). Seventeen cases died within 30 days after transplantation. No donor factor was significantly associated with 30-day mortality. Univariate analysis of the 84 cases for development of the prediction model showed that IL-6, IL-8, TNF-alpha and IL-1beta were risk factors for mortality and IL-10 and IFN-gamma were protective factors. We analyzed the cytokine expression ratios of risk to protective cytokines. A stepwise logistic regression for 30-day mortality demonstrated that a model containing the ratio of IL-6/IL-10 was the most predictive (p = 0.0013). When applied to the remaining 85 cases for validation, the test of model fit was significant (p = 0.039). Using the cytokine ratio, we were able to define three risk groups with striking differences in survival (p = 0.0003). Multi-cytokine analysis of the donor lung graft with qRT-PCR shows significant promise as a strategy to biologically evaluate the donor lung prior to implantation.     

Health‐related quality of life in multiple system atrophy

Although multiple system atrophy (MSA) is a neurodegenerative disorder leading to progressive disability and decreased life expectancy, little is known about patients' own evaluation of their illness and factors associated with poor health‐related quality of life (Hr‐QoL). We, therefore, assessed Hr‐QoL and its determinants in MSA. The following scales were applied to 115 patients in the European MSA‐Study Group (EMSA‐SG) Natural History Study: Medical Outcome Study Short Form (SF‐36), EQ‐5D, Beck Depression Inventory (BDI), Mini‐Mental state examination (MMSE), Unified MSA Rating Scale (UMSARS), Hoehn & Yahr (H&Y) Parkinson's disease staging scale, Composite Autonomic Symptom Scale (COMPASS), and Parkinson's Disease Sleep Scale (PDSS). Forty‐six percent of patients had moderate to severe depression (BDI ≥ 17); Hr‐QoL scores on the SF‐36 and EQ‐5D were significantly impaired. Pain, the only domain with similar scores in MSA and published PD patients, was reported more frequently in patients with MSA‐P (predominantly parkinsonian motor subtype) than MSA‐C (predominantly cerebellar motor subtype; 76% vs. 50%; P = 0.005). Hr‐QoL scores correlated most strongly with UMSARS motor, COMPASS, and BDI scores but not with MMSE scores, age at onset, or disease duration. The COMPASS and UMSARS activities of daily living scores were moderate‐to‐strong predictors for the SF‐36 physical summary score and the BDI and UMSARS motor scores for the SF‐36 mental summary score. This report is the first study to show that Hr‐QoL is significantly impaired in MSA. Although not all possible factors related to impaired Hr‐QoL in MSA could be assessed, autonomic dysfunction, motor impairment, and depression were most closely associated with poor Hr‐QoL, and therapeutic management, therefore, should concentrate upon these aspects of the disease. © 2006 Movement Disorder Society